Dr. Mujais is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2742 The Mews
Northbrook, IL 60062Phone+1 847-224-5802
Summary
- Dr. Salim Mujais is a nephrologist in Northbrook, IL. He received his medical degree from American University of Beirut Faculty of Medicine and has been in practice 39 years. He also speaks multiple languages, including French and Arabic. He is experienced in nephrology, transplant immunology, and autoimmune diseases.
Education & Training
- American University of Beirut Faculty of MedicineClass of 1978
- American University of BeirutB.S., Biology/Chemistry, With Distinction, 1974
Certifications & Licensure
- IL State Medical License 1981 - 2017
Awards, Honors, & Recognition
- Who's Who in America 2004
- President's Award for Leadership, Renal Division Baxter Healthcare, 2002
- Dean Award, Outstanding Basic Science Teacher Award Northwestern University Medical School, 1996
- Join now to see all
Publications & Presentations
PubMed
- Commentary on: Pharmacist-driven interventions to de-escalate urinary antimuscarinics in the Program of All-Inclusive Care for the Elderly.Daniel Snyder, Salim Mujais
Journal of the American Geriatrics Society. 2023-06-01 - 5 citationsComment on: Pharmacist-driven interventions to de-escalate urinary antimuscarinics in the Programs of All-Inclusive Care for the Elderly.Daniel Snyder, Salim Mujais
Journal of the American Geriatrics Society. 2023-03-01 - 69 citationsExposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous FungiAmit Desai, Laura L. Kovanda, William W. Hope, David R. Andes, Johan W. Mouton
Antimicrobial Agents and Chemotherapy. 2017-12-01
Journal Articles
- Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT studyMalik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R, Mujais SK, Schaddelee MP, de Koning P, Kaibara A, Moy SS, Keirns JJ, Clin Pharmacol Ther, 12/1/2012
- Modern peritoneal dialysis: Concepts and approachesMujais S, Holmes C, Kidney Int, 1/1/2006
- Glucose sparing in peritoneal dialysis: Implications and metricsHolmes C, Mujais S, Kidney Int, 1/1/2006
- Join now to see all
Books/Book Chapters
Press Mentions
- Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 Valent MAPS™ Vaccine for Streptococcus PneumoniaeJuly 12th, 2021
- FDA Accepts for Priority Review the New Drug Application for Mirabegron for Oral Suspension and Supplemental New Drug Application for Myrbetriq® (Mirabegron) Tablets in Pediatric PatientsJanuary 6th, 2021
- FDA Fast-Tracks Therapy for Patients at Risk for Acute Kidney Injury After CABG/Valve SurgeryOctober 29th, 2019
- Join now to see all
Other Languages
- French, Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: